vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $18.7M, roughly 1.1× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -84.4%, a 83.6% gap on every dollar of revenue. On growth, CytomX Therapeutics, Inc. posted the faster year-over-year revenue change (-25.7% vs -65.2%). CytomX Therapeutics, Inc. produced more free cash flow last quarter ($-15.8M vs $-39.7M). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
CTMX vs TRDA — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $20.6M |
| Net Profit | $-154.0K | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | -106.0% |
| Net Margin | -0.8% | -84.4% |
| Revenue YoY | -25.7% | -65.2% |
| Net Profit YoY | 97.6% | -173.8% |
| EPS (diluted) | — | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $18.7M | — | ||
| Q1 25 | $50.9M | $20.6M | ||
| Q4 24 | $38.1M | $37.4M | ||
| Q3 24 | $33.4M | $19.6M | ||
| Q2 24 | $25.1M | $94.7M | ||
| Q1 24 | $41.5M | $59.1M | ||
| Q4 23 | $26.6M | $41.8M | ||
| Q3 23 | $26.4M | $43.7M |
| Q2 25 | $-154.0K | — | ||
| Q1 25 | $23.5M | $-17.3M | ||
| Q4 24 | $18.9M | $1.1M | ||
| Q3 24 | $5.7M | $-14.0M | ||
| Q2 24 | $-6.5M | $55.0M | ||
| Q1 24 | $13.8M | $23.5M | ||
| Q4 23 | $837.0K | $-9.5M | ||
| Q3 23 | $3.0M | $35.5M |
| Q2 25 | -6.9% | — | ||
| Q1 25 | 44.4% | -106.0% | ||
| Q4 24 | 46.4% | -15.7% | ||
| Q3 24 | 12.3% | -110.7% | ||
| Q2 24 | -33.7% | 56.4% | ||
| Q1 24 | 28.1% | 35.7% | ||
| Q4 23 | -2.3% | 11.7% | ||
| Q3 23 | 11.8% | 32.0% |
| Q2 25 | -0.8% | — | ||
| Q1 25 | 46.2% | -84.4% | ||
| Q4 24 | 49.6% | 3.0% | ||
| Q3 24 | 17.2% | -71.7% | ||
| Q2 24 | -26.0% | 58.1% | ||
| Q1 24 | 33.3% | 39.7% | ||
| Q4 23 | 3.1% | -22.8% | ||
| Q3 23 | 11.3% | 81.1% |
| Q2 25 | — | — | ||
| Q1 25 | — | $-0.42 | ||
| Q4 24 | — | $-0.20 | ||
| Q3 24 | — | $-0.35 | ||
| Q2 24 | — | $1.55 | ||
| Q1 24 | — | $0.68 | ||
| Q4 23 | — | $-0.23 | ||
| Q3 23 | — | $1.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $417.3M |
| Total Assets | $175.1M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | $67.8M | ||
| Q4 24 | $38.1M | $101.2M | ||
| Q3 24 | $40.6M | $78.0M | ||
| Q2 24 | $43.2M | $185.3M | ||
| Q1 24 | $36.2M | $68.4M | ||
| Q4 23 | $17.2M | $67.6M | ||
| Q3 23 | $26.0M | $51.9M |
| Q2 25 | $119.9M | — | ||
| Q1 25 | $25.0M | $417.3M | ||
| Q4 24 | $-456.0K | $428.7M | ||
| Q3 24 | $-23.5M | $422.4M | ||
| Q2 24 | $-31.2M | $429.9M | ||
| Q1 24 | $-31.7M | $269.4M | ||
| Q4 23 | $-47.4M | $242.4M | ||
| Q3 23 | $-51.2M | $246.7M |
| Q2 25 | $175.1M | — | ||
| Q1 25 | $98.5M | $486.5M | ||
| Q4 24 | $120.5M | $526.3M | ||
| Q3 24 | $139.0M | $554.6M | ||
| Q2 24 | $159.2M | $582.0M | ||
| Q1 24 | $184.7M | $510.8M | ||
| Q4 23 | $201.8M | $469.2M | ||
| Q3 23 | $221.2M | $485.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-38.5M |
| Free Cash FlowOCF − Capex | $-15.8M | $-39.7M |
| FCF MarginFCF / Revenue | -84.6% | -192.9% |
| Capex IntensityCapex / Revenue | 0.1% | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.0M | $-38.5M | ||
| Q4 24 | $-19.9M | $-31.6M | ||
| Q3 24 | $-20.7M | $-24.3M | ||
| Q2 24 | $-19.5M | $39.8M | ||
| Q1 24 | $-26.0M | $-25.5M | ||
| Q4 23 | $-22.0M | $-4.0M | ||
| Q3 23 | $-18.2M | $-24.5M |
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | $-39.7M | ||
| Q4 24 | $-20.0M | $-32.2M | ||
| Q3 24 | $-20.7M | $-24.9M | ||
| Q2 24 | $-19.6M | $38.8M | ||
| Q1 24 | $-26.2M | $-26.4M | ||
| Q4 23 | $-22.2M | $-5.0M | ||
| Q3 23 | $-18.3M | $-25.9M |
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | -192.9% | ||
| Q4 24 | -52.5% | -86.2% | ||
| Q3 24 | -62.1% | -127.3% | ||
| Q2 24 | -78.2% | 41.0% | ||
| Q1 24 | -63.1% | -44.6% | ||
| Q4 23 | -83.5% | -11.9% | ||
| Q3 23 | -69.2% | -59.3% |
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | 5.6% | ||
| Q4 24 | 0.2% | 1.7% | ||
| Q3 24 | 0.1% | 3.3% | ||
| Q2 24 | 0.4% | 1.1% | ||
| Q1 24 | 0.3% | 1.4% | ||
| Q4 23 | 1.0% | 2.3% | ||
| Q3 23 | 0.0% | 3.3% |
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | -27.94× | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | -1.89× | -1.09× | ||
| Q4 23 | -26.24× | — | ||
| Q3 23 | -6.10× | -0.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
TRDA
Segment breakdown not available.
